Attached files

file filename
10-K - ANNUAL REPORT - Adamis Pharmaceuticals Corpadmp-10k_123120.htm
EX-32.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER - Adamis Pharmaceuticals Corpex32-2.htm
EX-32.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER - Adamis Pharmaceuticals Corpex32-1.htm
EX-31.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER - Adamis Pharmaceuticals Corpex31-2.htm
EX-31.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER - Adamis Pharmaceuticals Corpex31-1.htm
EX-23.2 - CONSENT OF MAYER HOFFMAN MCCANN P.C. - Adamis Pharmaceuticals Corpex23-2.htm
EX-21.1 - SUBSIDIARIES - Adamis Pharmaceuticals Corpex21-1.htm
EX-10.73 - PROMISSORY NOTE DATED MARCH 15, 2021 - Adamis Pharmaceuticals Corpex10-73.htm
EX-10.72 - LEASE AGREEMENT - Adamis Pharmaceuticals Corpex10-72.htm
EX-10.20 - FIRST AMENDMENT TO LEASE - Adamis Pharmaceuticals Corpex10-20.htm
EX-4.6 - DESCRIPTION OF CAPITAL STOCK - Adamis Pharmaceuticals Corpex4-6.htm
 

Adamis Pharmaceuticals Corporation 10-K

  

Exhibit 23.1 

 

 

Consent of Independent Registered Public Accounting Firm

 

Adamis Pharmaceuticals Corporation

11682 El Camino Real, Suite #300

San Diego, CA 92130

 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-159229, 333-169106, 333-175383, 333-194635, 333-201742, 333-211773, 333-218945, 333-226230, and 333-229379), and Form S-3 (Nos. 333-196976, 333-199454, 333-200447, 333-209401, 333-212880, 333-217400, 333-217408, 333-226100 and 333-249331) of Adamis Pharmaceuticals Corporation and Subsidiaries (the “Company”) of our report dated April 15, 2021, relating to the consolidated financial statements, which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

 

 

 

 

/s/ BDO USA, LLP

 

San Diego, CA 92130

April 15, 2021